| 前收市價 | 31.500 |
| 開市 | 31.100 |
| 買盤 | 31.000 x 無 |
| 賣出價 | 31.050 x 無 |
| 今日波幅 | 30.300 - 31.800 |
| 52 週波幅 | 11.360 - 43.600 |
| 成交量 | |
| 平均成交量 | 5,315,664 |
| 市值 | 26.808B |
| Beta 值 (5 年，每月) | 0.89 |
| 市盈率 (最近 12 個月) | 1.97 |
| 每股盈利 (最近 12 個月) | 15.750 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
- Benzinga
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
HUTCHMED (China) Limited (NASDAQ: HCM) has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (NYSE: TAK) to further the global development, commercialization, and manufacture of fruquintinib outside China. Fruquintinib is orally administered and can potentially be used across subtypes of metastatic colorectal cancer (CRC), regardless of biomarker status. Results of the FRESCO-2 Phase 3 trial of fruquintinib in refractory metastatic CRC were pr
- Benzinga
Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study
HUTCHMED (China) Limited (NASDAQ: HCM) announced initial results from FRUTIGA Phase 3 trial of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful. The other primary endpoint of overall survival (OS) was not statistically significant per the pre-specified statistica
- Benzinga
HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer
HUTCHMED (China) Limited (NASDAQ: HCM) announced summary results of the 691-patient trial of fruquintinib. These results have been shared in an abstract of the upcoming presentation at the European Society for Medical Oncology Congress 2022. The MRCT FRESCO-2 study demonstrated that treatment with fruquintinib resulted in a statistically significant and clinically meaningful increase in the primary overall survival (OS) endpoint and key secondary progression-free survival (PFS) endpoint compared
